top of page
Browse by category
Search


Vogenx initiates EMERGE study of Mizagliflozin for post-bariatric hypoglycaemia
Vogenx has initiated the EMERGE (VGX-001-013) study - its Phase 2b clinical trial evaluating mizagliflozin for the treatment of post-bariatric hypoglycaemia (PBH). There are currently no therapeutics approved by the FDA for the treatment of PBH. EMERGE is a randomised, placebo-controlled, double-blind, parallel-group Phase 2b study designed to enrol approximately 36 adults who underwent bariatric surgery more than 12 months prior and who experience recurrent reactive hypoglyc


Vogenx announces positive results from second phase 2 study of mizagliflozin in post-bariatric hypoglycaemia
Vogenx has announced positive results from study VGX 001-012 evaluating mizagliflozin in patients diagnosed with post-bariatric...


Last patient receives Mizagliflozin in Phase 2 clinical study for the treatment of post-bariatric hypoglycaemia
Vogenx has completed dosing of the last patient in its Phase 2 clinical study VGX-001-012 evaluating Mizagliflozin in patients diagnosed...


Enrolment complete in Vogenx’ Phase 2 Trial of mizagliflozin for post-bariatric hypoglycaemia
Vogenx has completed patient enrolment of a mid-Phase 2 clinical dose ranging study (VGX-001-012) evaluating mizagliflozin in patients...


Positive results for mizagliflozin in post-bariatric hypoglyceamia patients
Vogenx has announced positive results from its VGX 001-011 study, a phase 2 multi-centre, randomised, sequential crossover, single...
Browse by tag






bottom of page
